Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success Benjamin M Greenberg Donna Graves Gina Remington Paula Hardeman Martha Mann Nitin Karandikar Olaf Stuve Nancy Monson Elliot Frohman University of Texas Southwestern Medical Center, Dallas, TX, USA Benjamin M. Greenberg, MD, MHS, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8806, USA. Email: benjamin.greenberg@utsouthwestern.edu Abstract Background: Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis.
A Benign Form of Neuromyelitis Optica Does It Exist? Nicolas Collongues, MD; Philippe Cabre, MD, PhD; Romain Marignier, MD; H?l?ne Z?phir, MD; Caroline Papeix, MD; Bertrand Audoin, MD, PhD; Christine Lebrun-Frenay, MD; Jean Pelletier, MD, PhD; Bertrand Fontaine, MD, PhD; Patrick Vermersch, MD, PhD; Christian Confavreux, MD, PhD; J?r?me de Seze, MD, PhD; Group Members for NOMADMUS and CF-SEP Arch Neurol. ?2011;68(7):918-924
In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90% of cases refractory to standard therapies.
BACKGROUND: Recently, a highly specific serum autoantibody was discovered in patients with neuromyelitis optica, called NMO-IgG, and aquaporin-4, the most abundant water channel in the CNS, was identified as the target antigen.